These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38336636)

  • 1. Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa.
    McCallion J; Borsi A; Noel W; Lee J; Karmous W; Sattler S; Boggia GM; Hardy EJ; Mitchell CR; Mitchell SA; Gilhus NE
    BMC Neurol; 2024 Feb; 24(1):61. PubMed ID: 38336636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis.
    Meisel A; Saccà F; Spillane J; Vissing J;
    Eur J Neurol; 2024 Jul; 31(7):e16280. PubMed ID: 38523419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
    Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
    Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events.
    Zhdanava M; Pesa J; Boonmak P; Cai Q; Pilon D; Choudhry Z; Souayah N
    Curr Med Res Opin; 2024 Jul; 40(7):1145-1153. PubMed ID: 38745448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient's Perspective: A Qualitative Study.
    Jackson K; Parthan A; Lauher-Charest M; Broderick L; Law N; Barnett C
    Neurol Ther; 2023 Feb; 12(1):107-128. PubMed ID: 36322146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy.
    Saccà F; Salort-Campana E; Jacob S; Cortés-Vicente E; Schneider-Gold C
    Eur J Neurol; 2024 Jun; 31(6):e16180. PubMed ID: 38117543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study.
    Hendricks TM; Bhatti MT; Hodge DO; Chen JJ
    Am J Ophthalmol; 2019 Sep; 205():99-105. PubMed ID: 31077669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics of ocular myasthenia gravis and outcomes of secondary generalisation: a systematic review protocol.
    Fang CEH; Bokre D; Wong SH
    BMJ Open; 2022 Sep; 12(9):e060259. PubMed ID: 36127086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience of Daily Life with Generalized Myasthenia Gravis: A Qualitative Investigation and Assessment of Instrument Content Validity.
    Hartford CA; Sherman SA; Karantzoulis S; Guillemin I; Phinney MG; Kelly KL; Negron KE; Raja SM; Rofail D
    Neurol Ther; 2023 Dec; 12(6):2079-2099. PubMed ID: 37747661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody.
    Apinyawasisuk S; Chongpison Y; Thitisaksakul C; Jariyakosol S
    Am J Ophthalmol; 2020 Jan; 209():10-17. PubMed ID: 31562855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to treatment in pediatric ocular myasthenia gravis.
    Xu L; Castro D; Reisch JS; Iannaccone ST
    Muscle Nerve; 2020 Feb; 61(2):226-230. PubMed ID: 31650555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.
    Allen JA; Scala S; Jones HR
    Muscle Nerve; 2010 Mar; 41(3):379-84. PubMed ID: 19918767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causes of symptom dissatisfaction in patients with generalized myasthenia gravis.
    Andersen LK; Jakobsson AS; Revsbech KL; Vissing J
    J Neurol; 2022 Jun; 269(6):3086-3093. PubMed ID: 34806129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Burden Patients with Myasthenia Gravis Experience in Terms of Breathing, Fatigue, Sleep, Mental Health, Discomfort and Usual Activities in Comparison to the General Population.
    Dewilde S; Phillips G; Paci S; De Ruyck F; Tollenaar NH; Janssen MF
    Adv Ther; 2024 Jan; 41(1):271-291. PubMed ID: 37921955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benefits and tolerance of exercise in myasthenia gravis (MGEX): study protocol for a randomised controlled trial.
    Birnbaum S; Hogrel JY; Porcher R; Portero P; Clair B; Eymard B; Demeret S; Bassez G; Gargiulo M; Louët E; Berrih-Aknin S; Jobic A; Aegerter P; Thoumie P; Sharshar T;
    Trials; 2018 Jan; 19(1):49. PubMed ID: 29347991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Thymoma and Thymic Hyperplasia as Prognostic Risk Factors for Secondary Generalisation in Adults with Ocular Myasthenia Gravis: A Systematic Narrative Review.
    Wilson L; Davis H
    Br Ir Orthopt J; 2023; 19(1):108-119. PubMed ID: 38046270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatigue is a relevant outcome in patients with myasthenia gravis.
    Tran C; Bril V; Katzberg HD; Barnett C
    Muscle Nerve; 2018 Aug; 58(2):197-203. PubMed ID: 29342314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic.
    Kısabay A; Özdemir HN; Gökçay F; Çelebisoy N
    Acta Neurol Belg; 2022 Apr; 122(2):337-344. PubMed ID: 33544334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
    Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
    Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.